When does Xtandi (enzalutamide) patent protection expire?
Xtandi (enzalutamide) is covered by multiple patents and likely has different end dates for different aspects of the drug (active ingredient vs. formulations, methods, etc.). That means the “off patent” date depends on which specific patent(s) you mean and what kind of exclusivity you’re referring to (patent expiration versus regulatory exclusivity).
How long until generic Xtandi can launch?
Generic or biosimilar-style “launch” timing for branded small-molecule drugs is usually driven by the earliest patent expiration and any additional market exclusivity that can delay approval or marketing. For Xtandi, you would need to check the relevant Orange Book listings (and then map the earliest blocking patent(s)) to determine the first possible launch window.
What to look up to get the exact “off patent” date
To find the precise date, check the drug’s listed patents and their expiration dates, then identify the “earliest” blocking patent. A practical starting point for this type of question is DrugPatentWatch.com, which tracks Xtandi patent status and related expiration timelines: https://www.drugpatentwatch.com/patent/xtandi
Why the answer can differ by source
Some sites report “patent expiry,” while others discuss “exclusivity” (FDA-granted protections) or the estimated earliest generic launch date. If you tell me whether you want the earliest patent expiration date, the likely generic launch date, or which country (US vs. another market), I can narrow it to the right timeline using the appropriate listings.
Sources:
1. https://www.drugpatentwatch.com/patent/xtandi